Results 11 to 20 of about 192,949 (111)

Sensitivity and specificity of the anti-TK1-sdAb fragments.

, 2022
A) The 14 anti-TK1 sdAb fragments were tested against a minimal fixed concentration of 23 ng/ml of human TK1 produced in human cells (H-TK1). The sdAbs 4-H-TK1_A1 and 4-H-TK1_D1 produced the highest signals.
Jonathan R. Skidmore (12191914), Kim L. O’Neill (8724423), Edwin J. Velazquez (8724405), Tyler B. Humpherys (12191905), David M. Bellini (12191911), Richard A. Robison (2116180), Jordan D. Cress (8724417), Kathryn R. Smith (12191917), Toni O. Mortimer (12191908), Scott K. Weber (12191920)   +9 more
core   +1 more source

The 3D structure of the two best anti-TK1-sdAb fragments based on their deduced amino acid sequences.

, 2022
The anti-TK1-sdAb fragments were modeled using the GalaxyWeb TBM server. The most stable structures were then visualized using the VMD 1.9.3 software. CDRs were mapped by analyzing the anti-TK1 sdAb amino acid sequences with the IgBlast tool from NCBI. A)
Jonathan R. Skidmore (12191914), Kim L. O’Neill (8724423), Edwin J. Velazquez (8724405), Tyler B. Humpherys (12191905), David M. Bellini (12191911), Richard A. Robison (2116180), Jordan D. Cress (8724417), Kathryn R. Smith (12191917), Toni O. Mortimer (12191908), Scott K. Weber (12191920)   +9 more
core   +1 more source

Amplification and ligation of anti-TK1-dAb fragments into the pET-scFv-T expression vector.

, 2022
A) a representative image of a PCR showing amplification of anti-TK1 dAb fragments. B) Restriction enzyme analysis with NcoI and NotI enzymes of pET-anti-TK1-dAb constructs. C) Map of a pET-anti-TK1-dAb construct.
Jonathan R. Skidmore (12191914), Kim L. O’Neill (8724423), Edwin J. Velazquez (8724405), Tyler B. Humpherys (12191905), David M. Bellini (12191911), Richard A. Robison (2116180), Jordan D. Cress (8724417), Kathryn R. Smith (12191917), Toni O. Mortimer (12191908), Scott K. Weber (12191920)   +9 more
core   +1 more source

Enrichment of anti-TK1-sdAb phages through 5 rounds of selection.

, 2022
Enrichment of anti-TK1-sdAb phages through 5 rounds of selection.
Jonathan R. Skidmore (12191914), Kim L. O’Neill (8724423), Edwin J. Velazquez (8724405), Tyler B. Humpherys (12191905), David M. Bellini (12191911), Richard A. Robison (2116180), Jordan D. Cress (8724417), Kathryn R. Smith (12191917), Toni O. Mortimer (12191908), Scott K. Weber (12191920)   +9 more
core   +1 more source

Selection and expression of anti-TK1-sdAb phages.

, 2022
A) Analysis of 80 clones using monoclonal phage ELISA was performed after each round of selection. B) Polyclonal phage ELISA using the total purified phages per round of selection.
Jonathan R. Skidmore (12191914), Kim L. O’Neill (8724423), Edwin J. Velazquez (8724405), Tyler B. Humpherys (12191905), David M. Bellini (12191911), Richard A. Robison (2116180), Jordan D. Cress (8724417), Kathryn R. Smith (12191917), Toni O. Mortimer (12191908), Scott K. Weber (12191920)   +9 more
core   +1 more source

Characterization of TK1 antibodies.

, 2022
(A) An SDS-PAGE was performed with a 4% - 20% gradient gel for analysis of purified recombinant TK1, followed by Coomassie Blue staining, Lane 1: BSA (2.00 μg), Lane 2: Thymidine Kinase 1 (2.00 μg).
K. K. Jagarlamudi (13919582), Osredkar J. (8057045), Eriksson S. (13919591), Swinkels L. (13919585), Venge P. (13919588), Zupan M. (4152811)   +5 more
core   +1 more source

Distribution of TK1 protein and TK1 activity values in sera from patients with breast cancer.

, 2022
(A) TK1 protein values in sera from blood donors (●) and patients with breast cancer (■). (B) TK1 activity levels in sera from blood donors (●) and patients with breast cancer (■). (C) Comparison of TK1 protein levels in sera from blood donors (●), T1 (■)
K. K. Jagarlamudi (13919582), Osredkar J. (8057045), Eriksson S. (13919591), Swinkels L. (13919585), Venge P. (13919588), Zupan M. (4152811)   +5 more
core   +1 more source

The distribution of serum TK1 protein and TK1 activity in blood donor samples (n = 159).

, 2022
(A) Serum TK1 protein distribution in blood donor sera (n = 159) (B) A comparison of TK1 concentrations in sera from blood donor men below 60 years (●) and men above 60 years (■). The error bars indicate the median (red). (C) Serum TK1 activity levels in
K. K. Jagarlamudi (13919582), Osredkar J. (8057045), Eriksson S. (13919591), Swinkels L. (13919585), Venge P. (13919588), Zupan M. (4152811)   +5 more
core   +1 more source

TK1 protein and TK1 activity values in sera from patients with prostate cancer.

, 2022
(A) TK1 protein values in sera from blood donors (●) and patients with prostate cancer (■). (B) TK1 activity levels in sera from blood donors (●) and patients with prostate cancer (■).
K. K. Jagarlamudi (13919582), Osredkar J. (8057045), Eriksson S. (13919591), Swinkels L. (13919585), Venge P. (13919588), Zupan M. (4152811)   +5 more
core   +1 more source

TK1 protein and TK1 activity levels in sera from patients with hematological malignancies.

, 2022
(A) TK1 protein distributions in sera from blood donors (●) and patients with hematological malignancies (■). (B) TK1 activity levels in sera from blood donors (●) and patients with hematological malignancies (■).
K. K. Jagarlamudi (13919582), Osredkar J. (8057045), Eriksson S. (13919591), Swinkels L. (13919585), Venge P. (13919588), Zupan M. (4152811)   +5 more
core   +1 more source